JP2014507442A5 - - Google Patents

Download PDF

Info

Publication number
JP2014507442A5
JP2014507442A5 JP2013555521A JP2013555521A JP2014507442A5 JP 2014507442 A5 JP2014507442 A5 JP 2014507442A5 JP 2013555521 A JP2013555521 A JP 2013555521A JP 2013555521 A JP2013555521 A JP 2013555521A JP 2014507442 A5 JP2014507442 A5 JP 2014507442A5
Authority
JP
Japan
Prior art keywords
expression cassette
tbx5
mef2c
subject
hand2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013555521A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014507442A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/026113 external-priority patent/WO2012116064A1/en
Publication of JP2014507442A publication Critical patent/JP2014507442A/ja
Publication of JP2014507442A5 publication Critical patent/JP2014507442A5/ja
Pending legal-status Critical Current

Links

JP2013555521A 2011-02-22 2012-02-22 心臓線維芽細胞の心筋細胞への再プログラム化による心臓修復 Pending JP2014507442A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161445390P 2011-02-22 2011-02-22
US61/445,390 2011-02-22
PCT/US2012/026113 WO2012116064A1 (en) 2011-02-22 2012-02-22 Cardiac repair by reprogramming of cardiac fibroblasts into cardiomyocytes

Publications (2)

Publication Number Publication Date
JP2014507442A JP2014507442A (ja) 2014-03-27
JP2014507442A5 true JP2014507442A5 (enExample) 2015-04-16

Family

ID=45922797

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013555521A Pending JP2014507442A (ja) 2011-02-22 2012-02-22 心臓線維芽細胞の心筋細胞への再プログラム化による心臓修復

Country Status (6)

Country Link
US (2) US9017661B2 (enExample)
EP (1) EP2678354A1 (enExample)
JP (1) JP2014507442A (enExample)
AU (1) AU2012220702B2 (enExample)
CA (1) CA2827329A1 (enExample)
WO (1) WO2012116064A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6236393B2 (ja) * 2011-11-09 2017-11-22 セダーズ−シナイ メディカル センター 転写因子に基づくペースメーカー細胞の生成およびその使用方法
EP3060237B1 (en) * 2013-10-25 2021-08-18 Wayne State University Modified reprogramming protein for use in treating a cancer
JP2015213441A (ja) * 2014-05-08 2015-12-03 学校法人慶應義塾 心筋様細胞の作製方法及びそれに用いる培地
EP3177302A4 (en) * 2014-08-07 2018-04-11 Duke University Compositions and methods for the reprogramming of cells into cardiomyocytes
KR101530278B1 (ko) * 2014-09-04 2015-06-24 부산대학교 산학협력단 심근전환유전자 및 심혈관재생유전자를 포함하는 아데노부속바이러스를 유효성분으로 포함하는, 허혈성 심장질환 예방 또는 치료용 조성물
US9885018B1 (en) * 2015-03-16 2018-02-06 The Regents Of The University Of Colorado, A Body Corporate High efficiency reprogramming of fibroblasts into cardiomyocytes
CN110997901A (zh) * 2017-06-21 2020-04-10 重组生物科技有限公司 细胞重编程为心肌细胞
US20210180023A1 (en) * 2017-08-15 2021-06-17 The Board Of Regents Of The University Of Texas System Cardiac repair by reprogramming of adult cardiac fibroblasts into cardiomyocytes
US12042525B2 (en) 2018-01-05 2024-07-23 University Of Houston System Serum response factor regenerates senescent cells
GB2571704A (en) * 2018-02-22 2019-09-11 Georg August Univ Gottingen Stiftung Offentlichen Rechts Univer Sitatsmedzin Goettingen Prevention or treatment of cardiac arrhytmia and sudden cardiac death
AU2019333315B2 (en) 2018-08-30 2022-09-29 Tenaya Therapeutics, Inc. Cardiac cell reprogramming with myocardin and ASCL1

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
WO1999062940A2 (en) 1998-05-30 1999-12-09 Collateral Therapeutics, Inc. Methods of altering cardiac cell phenotype
AU2002216751A1 (en) * 2000-06-30 2002-01-14 Collateral Therapeutics, Inc. Dual recombinant gene therapy compositions and methods of use
WO2007056759A2 (en) * 2005-11-08 2007-05-18 University Of South Florida Improved method of stem cell therapy for cardiovascular repair
US20100172883A1 (en) * 2007-01-19 2010-07-08 Bruneau Benoit Gaetan Methods of generating cardiomyocytes
WO2009145761A1 (en) * 2008-05-27 2009-12-03 Mayo Foundation For Medical Education And Research Methods and materials for using cells to treat heart tissue
AU2009329893A1 (en) * 2008-12-23 2011-06-30 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification
EP2563907B1 (en) * 2010-04-28 2019-06-19 The J. David Gladstone Institutes Methods for generating cardiomyocytes
CN102947444A (zh) * 2010-06-23 2013-02-27 帷幄生物技术公司 用于治疗心血管疾病的非遗传修饰性重编程细胞的组合物和方法

Similar Documents

Publication Publication Date Title
JP2014507442A5 (enExample)
Keating et al. Nesiritide: a review of its use in acute decompensated heart failure
Colucci Nesiritide for the treatment of decompensated heart failure
Kerkelä et al. Natriuretic peptides in the regulation of cardiovascular physiology and metabolic events
Fedele et al. Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms
Lutomsky et al. Catheter ablation of paroxysmal atrial fibrillation improves cardiac function: a prospective study on the impact of atrial fibrillation ablation on left ventricular function assessed by magnetic resonance imaging
Boerrigter et al. Des-serine-proline brain natriuretic peptide 3–32 in cardiorenal regulation
JP2011522824A5 (enExample)
Yahud et al. Cannabis induced cardiac arrhythmias: a case series
Pilote et al. Stiff left atrial syndrome.
Biondi The management of thyroid abnormalities in chronic heart failure
Granton et al. Management of severe pulmonary arterial hypertension
Chen et al. CRRL269: a novel designer and renal-enhancing pGC-A peptide activator
Parle et al. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure–a single-centre experience
Vonder Muhll et al. Applying standard therapies to new targets: the use of ACE inhibitors and B-blockers for heart failure in adults with congenital heart disease
Rossi et al. Effects of ivabradine on right ventricular systolic function in patients with chronic obstructive pulmonary disease and cor pulmonale
Bettencourt Brain natriuretic peptide (nesiritide) in the treatment of heart failure
Shang et al. Peri‐operative Takotsubo syndrome after non‐cardiac surgery: a retrospective nested case–control study
Toller et al. Acute perioperative heart failure
Katsaragakis et al. Prophylactic preoperative levosimendan administration in heart failure patients undergoing elective non-cardiac surgery: a preliminary report
Sagawa et al. Long-term performance of right ventricular implantable cardioverter-defibrillator leads in arrhythmogenic right ventricular cardiomyopathy and hypertrophic cardiomyopathy
Ji et al. Combination of irbesartan and amiodarone to maintain sinus rhythm in patients with persistent atrial fibrillation after rheumatic valve replacement
Savale et al. Management of acutely decompensated pulmonary hypertension
Rennyson et al. Recurrent, severe, and rapidly reversible apical ballooning syndrome in status asthmaticus
Uriel et al. Spotlight on new therapies in heart failure